Effect of Genetic Background on Manifestation of Progressive Fibrosing Interstitial Lung Diseases

被引：0
|
作者：
Sterclova, M.
Sikorova, K.
Kishore, A.
Petrek, M.
Vasakova, M.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7144
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Reply to comment on "The natural history of progressive fibrosing interstitial lung diseases"
    Brown, Kevin K.
    Schlenker-Herceg, Rozsa
    Wells, Athol U.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (06)
  • [32] Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases
    Fischer, Aryeh
    Distler, Joerg
    CLINICAL RHEUMATOLOGY, 2019, 38 (10) : 2673 - 2681
  • [33] Does HRCT pattern influence the effect of nintedanib in patients with progressive fibrosing interstitial lung diseases?
    Behr, J.
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J. W.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R. G.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    PNEUMOLOGIE, 2021, 75 : S31 - S32
  • [34] Does HRCT Pattern Influence the Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases?
    Brown, K. K.
    Walsh, S. L. F.
    Devaraj, A.
    Song, J.
    Wuyts, W. A.
    Valenzuela, C.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [35] Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype
    Inoue, Yoshikazu
    Kaner, Robert J.
    Guiot, Julien
    Maher, Toby M.
    Tomassetti, Sara
    Moiseev, Sergey
    Kuwana, Masataka
    Brown, Kevin K.
    CHEST, 2020, 158 (02) : 646 - 659
  • [36] Management of Fibrosing Interstitial Lung Diseases
    Maher, Toby M.
    Wuyts, Wim
    ADVANCES IN THERAPY, 2019, 36 (07) : 1518 - 1531
  • [37] Management of Fibrosing Interstitial Lung Diseases
    Toby M. Maher
    Wim Wuyts
    Advances in Therapy, 2019, 36 : 1518 - 1531
  • [38] Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analyses from the INBUILD Trial
    Kolb, M. R.
    Flaherty, K. R.
    Silva, R. S.
    Prasse, A.
    Patel, N. M.
    Vancheri, C.
    Quaresma, M.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [39] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
    Matteson, Eric
    Kelly, Clive
    Distler, Joerg
    Mann-Vold, Anna Maria Hoff
    Seibold, James
    Mittoo, Shikha
    Distler, Oliver
    Goeldner, Rainer-Georg
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [40] Prevalence of progressive fibrosing interstitial lung disease
    Olson, Amy
    Hartmann, Nadine
    Schlenker-Herceg, Rozsa
    Wallace, Laura
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
12345